Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 19, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The filing details a specific change in the shareholding of the GlaxoSmithKline US Retirement Savings Plan ("the Plan"):
- Date of Movement: June 15, 2006
- Previous Holdings: 17,444,240 Ordinary Share ADRs
- New Holdings: 17,454,333 Ordinary Share ADRs
- Net Change: Increase of 10,093 ADRs
- Average Price: $55.40
This change resulted from a movement in the fund. The Plan is a discretionary fund for current and former employees. Two directors, Dr. J P Garnier and Dr. M Slaoui, are noted as potentially interested in the shares held in the fund in the same capacity as other employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a notification of a transaction under Disclosure Rule 3.1.4R(1)(b).
Investor Verification Points
- Verify the total number of ADRs held by the US Retirement Savings Plan as of June 15, 2006 (17,454,333).
- Confirm the average transaction price of $55.40 for the fund movement.
- Note that the increase in holdings was due to fund movement, not direct trading by the directors.
- Recognize that Dr. J P Garnier and Dr. M Slaoui have a potential interest in these shares as beneficiaries of the employee plan.